id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
91,,,,,,,,,,,,,,,2024-05-09T18:24:16+06:00,BSH - H12005092393,,Tucatinib + Capecitabine,2023-02-01,,"Post CT8 with Trastuzumab + Capecitabine, completed maintenance Trastuzumab (Toatl 17 cycles) on
30.05.2019,
• Xeloda + Lepatinib/Tykerb, started on 28.12.2019 (irregular due to intolerance)
• From 27.12.20 Single Capecitabine + Herceptin started, Cycle 6 Capecitabine till 24.04.21 > PD with
Axillary LNs
• Weekly Paclitaxel started from 05.05.21,Week 12 Paclitaxel is completed on 28.07.2021 & Cycle 12 with
Trastuzumab till 18.08.2021
• TDM-1 from 24.05.2022. Cycle 13 till on 31.01.2023Started Tucatinib + Capecitabine Feb 23> after 3 course SD",2023-11-30,,2024-01-27,,2023-11-30,,,Breast,87,,BSBSC-240000087,MARIYUM BEGUM,1713049680,1950-05-19,Female,,,,,Dr Ferdous Ara Begum,BSH,2.0,,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.3- Lower-inner quadrant of breast,Breast,Left,,,Progressed,Alive,PD,,,,,,,,,,,,,,,,,,,,,
